Almost two years on from its first observation, SARS-CoV-2 remains a virus of critical concern at a global scale.
As vaccines progress, there remains no commercial treatment after the virus has been contracted. The impact of these symptoms can be devastating and life-long.
Esfam Biotech has discovered a panel of molecules which, after computer-based design of a virus-binding target on the cell, is believed to block the SARS-CoV-2 virus from damaging infected cells.
Already confirmed in cell-based studies and animal models, our development pathway will see us in human clinical trials by the end of 2024.